EGFR and prostate carcinoma: DHT increases both epidermal growth factor receptor (EGFR) numbers and receptor–ligand affinity in androgen-sensitive prostate cancer cells; this correlates with increased EGF binding and an enhanced mitogenic response to EGF [76,77].